Compare Stocks: VXRT, RLMD, VREOD, and CGC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGC Canopy Growth	$0.97 +0.5%	$0.97	$0.84 ▼ $2.38	$434.97M	0.83	4.14 million shs	1.71 million shs
RLMD Relmada Therapeutics	$4.37 -3.7%	$5.34	$1.13 ▼ $8.00	$484.28M	0.45	1.09 million shs	847,506 shs
VREOD Vireo Growth	$9.95	$9.95	$8.91 ▼ $24.00	$450.88M	1.78	14,588 shs	N/A
VXRT Vaxart	$0.49 +0.4%	$0.53	$0.31 ▼ $0.84	$119.29M	1.06	290,092 shs	256,912 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGC Canopy Growth	-0.72%	-6.46%	+1.09%	-6.91%	-35.03%
RLMD Relmada Therapeutics	+1.79%	-0.22%	-14.34%	-28.05%	+219.72%
VREOD Vireo Growth	0.00%	0.00%	0.00%	-19.18%	-48.51%
VXRT Vaxart	-0.51%	-2.78%	-16.86%	-20.48%	+29.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGC Canopy Growth	$0.97 +0.5%	$0.97	$0.84 ▼ $2.38	$434.97M	0.83	4.14 million shs	1.71 million shs
RLMD Relmada Therapeutics	$4.37 -3.7%	$5.34	$1.13 ▼ $8.00	$484.28M	0.45	1.09 million shs	847,506 shs
VREOD Vireo Growth	$9.95	$9.95	$8.91 ▼ $24.00	$450.88M	1.78	14,588 shs	N/A
VXRT Vaxart	$0.49 +0.4%	$0.53	$0.31 ▼ $0.84	$119.29M	1.06	290,092 shs	256,912 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGC Canopy Growth	-0.72%	-6.46%	+1.09%	-6.91%	-35.03%
RLMD Relmada Therapeutics	+1.79%	-0.22%	-14.34%	-28.05%	+219.72%
VREOD Vireo Growth	0.00%	0.00%	0.00%	-19.18%	-48.51%
VXRT Vaxart	-0.51%	-2.78%	-16.86%	-20.48%	+29.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGC Canopy Growth	2.20	Hold	N/A	N/A
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	174.60% Upside
VREOD Vireo Growth	1.00	Sell	N/A	N/A
VXRT Vaxart	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest VXRT, RLMD, VREOD, and CGC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/9/2026	VXRT Vaxart	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/29/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/18/2026	RLMD Relmada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/18/2026	RLMD Relmada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/18/2026	RLMD Relmada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/15/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/5/2026	VREOD Vireo Growth	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGC Canopy Growth	$251.01M	1.74	N/A	N/A	$1.11 per share	0.88
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.94 per share	N/A
VREOD Vireo Growth	$268.77M	1.68	N/A	N/A	$8.73 per share	1.14
VXRT Vaxart	$237.26M	0.50	$0.10 per share	4.79	$0.34 per share	1.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGC Canopy Growth	-$190.29M	-$0.45	N/A	N/A	N/A	-65.33%	-21.91%	-14.34%	11/6/2026 (Estimated)
RLMD Relmada Therapeutics	-$57.38M	-$0.90	N/A	N/A	N/A	N/A	-47.52%	-43.97%	11/12/2026 (Estimated)
VREOD Vireo Growth	-$68.11M	-$3.30	N/A	11.06	N/A	-23.37%	-19.76%	-7.15%	N/A
VXRT Vaxart	$16.33M	$0.16	3.08	N/A	N/A	15.88%	53.04%	20.85%	11/12/2026 (Estimated)

Latest VXRT, RLMD, VREOD, and CGC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q1 2027	CGC Canopy Growth	-$0.04	-$0.02	+$0.02	-$0.02	$58.21 million	$142.62 million
8/6/2026	Q2 2026	RLMD Relmada Therapeutics	-$0.1995	-$0.11	+$0.0895	-$0.11	N/A	N/A
8/6/2026	Q2 2026	VXRT Vaxart	-$0.12	-$0.06	+$0.06	-$0.06	$26.21 million	$27.19 million
6/15/2026	Q4 2026	CGC Canopy Growth	-$0.06	-$0.17	-$0.11	-$0.05	$53.43 million	$51.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A
VREOD Vireo Growth	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGC Canopy Growth	0.31	3.04	2.39
RLMD Relmada Therapeutics	N/A	29.52	29.52
VREOD Vireo Growth	0.70	1.20	0.84
VXRT Vaxart	N/A	1.60	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGC Canopy Growth	3.33%
RLMD Relmada Therapeutics	45.24%
VREOD Vireo Growth	N/A
VXRT Vaxart	18.05%

Insider Ownership

Company	Insider Ownership
CGC Canopy Growth	0.35%
RLMD Relmada Therapeutics	14.50%
VREOD Vireo Growth	3.80%
VXRT Vaxart	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGC Canopy Growth	1,128	449.30 million	447.73 million	Optionable
RLMD Relmada Therapeutics	10	106.67 million	91.20 million	Optionable
VREOD Vireo Growth	500	45.32 million	43.59 million	Not Optionable
VXRT Vaxart	120	243.20 million	236.39 million	No Data

VXRT, RLMD, VREOD, and CGC Headlines

Recent News About These Companies

Vaxart Secures New European Patent Covering Oral Norovirus Vaccine Technology

August 27, 2026 | finance.yahoo.com

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

August 26, 2026 | globenewswire.com

Vaxart (OTCMKTS:VXRT) Shares Cross Below 200-Day Moving Average - Time to Sell?

August 26, 2026 | americanbankingnews.com

Vaxart (OTCMKTS:VXRT) Share Price Passes Below 200 Day Moving Average - Here's Why

August 26, 2026 | marketbeat.com

Vaxart (OTCMKTS:VXRT) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell?

August 18, 2026 | marketbeat.com

Vaxart Inc (VXRT) (Q2 2026) Earnings Call Highlights: Oral COVID Vaccine Shows Promise, Cash ...

August 10, 2026 | finance.yahoo.com

Vaxart Q2 Earnings Call Highlights

August 9, 2026 | marketbeat.com

Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding

August 8, 2026 | seekingalpha.com

Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results

August 6, 2026 | markets.businessinsider.com

Vaxart (OTCMKTS:VXRT) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

August 6, 2026 | marketbeat.com

Vaxart Q2 2026 earnings preview

August 5, 2026 | msn.com

Vaxart (VXRT) Expected to Post Earnings on Thursday

August 4, 2026 | marketbeat.com

Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET

July 30, 2026 | finance.yahoo.com

Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET

July 30, 2026 | globenewswire.com

Vaxart to Participate in BTIG Biotechnology Conference 2026

July 21, 2026 | finance.yahoo.com

Vaxart to Participate in BTIG Biotechnology Conference 2026

July 21, 2026 | globenewswire.com

Vaxart Announces Results of Annual Meeting of Stockholders

July 17, 2026 | finance.yahoo.com

Vaxart Announces Results of Annual Meeting of Stockholders

July 17, 2026 | globenewswire.com

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

July 6, 2026 | finance.yahoo.com

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

July 6, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VXRT, RLMD, VREOD, and CGC Company Descriptions

Canopy Growth NASDAQ:CGC

$0.97 +0.00 (+0.50%)

As of 04:00 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Relmada Therapeutics NASDAQ:RLMD

$4.37 -0.17 (-3.74%)

As of 04:00 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Vireo Growth OTCMKTS:VREOD

$9.95 0.00 (0.00%)

As of 09/2/2026

Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.

Vaxart OTCMKTS:VXRT

$0.49 +0.00 (+0.41%)

As of 03:58 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VXRT, RLMD, VREOD, and CGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VXRT, RLMD, VREOD, and CGC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VXRT, RLMD, VREOD, and CGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VXRT, RLMD, VREOD, and CGC Company Descriptions

Canopy Growth NASDAQ:CGC

Relmada Therapeutics NASDAQ:RLMD

Vireo Growth OTCMKTS:VREOD

Vaxart OTCMKTS:VXRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VXRT, RLMD, VREOD, and CGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VXRT, RLMD, VREOD, and CGC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VXRT, RLMD, VREOD, and CGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VXRT, RLMD, VREOD, and CGC Company Descriptions

Canopy Growth NASDAQ:CGC

Relmada Therapeutics NASDAQ:RLMD

Vireo Growth OTCMKTS:VREOD

Vaxart OTCMKTS:VXRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools